Core Insights - The IBI EXPO 2026 Biopharmaceutical Innovation Conference will provide a high-level platform for communication and collaboration in the innovative drug industry [1] - Recent favorable news in the innovative drug sector includes a significant increase in licensing agreements, with Chinese companies signing $137.7 billion in deals in 2025, nearly a tenfold increase from 2021 [1][2] - The trend of Chinese biopharmaceutical companies entering international licensing agreements is accelerating, with major collaborations such as the $8.85 billion deal between Innovent Biologics and Eli Lilly [1][5] Market Focus - The IBI EXPO 2026 conference serves as a catalyst for the innovative drug sector, highlighting the substantial growth in licensing agreements and the transition from research investment to commercial realization [2] - The number of licensing agreements reached 186 in 2025, with a total transaction value of $137.7 billion, marking a record high for the past decade [3][5] - Companies like Innovent Biologics and Rongchang Biopharma are transitioning from loss to profit, indicating a clear improvement in the overall profitability of the industry [2][3] Broker Insights - Open Source Securities notes that the period from 2017 to 2026 is a "golden decade" for Chinese pharmaceutical companies, with licensing agreements skyrocketing from $2.562 billion in 2017 to $137.7 billion in 2025 [3] - The overall revenue growth in innovative drugs is evident, with over 70% of companies reporting positive revenue growth in 2025, showcasing strong commercial capabilities [3] - The innovative drug sector has seen a price correction over the past two quarters, but long-term prospects remain positive, suggesting an increase in sector allocation [3] Related Industries - The innovative drug sector is transitioning from a research investment phase to a commercialization phase, with significant implications for the CXO (Contract Research Organization) industry, which is expected to benefit from increased orders [5] - The new business model of external licensing is expected to enhance the early-stage research pipeline, benefiting companies involved in drug discovery and clinical trials [4][5] - The trend of Chinese innovative drugs "going global" is becoming systematic, with major collaborations indicating a shift towards international development [5] Industry Chain Companies - Heng Rui Medicine is a representative company in the domestic chemical innovative drug sector, with a diverse pipeline and ongoing internationalization efforts [7] - Sanofi Biopharma has received approval for its self-developed monoclonal antibody, further enriching its commercial product pipeline [7] - Companies like Rongchang Biopharma and Ailis are demonstrating strong revenue growth and successful international collaborations, indicating a positive trend in the innovative drug sector [7][8]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][4] - The "Zhuomuniao Medical Model," the core engine of the hub, has achieved the top ranking in the "Medical Language Understanding" category on the MedBench evaluation platform, showcasing its leading position in the medical AI field [1][2] Company Overview - Zhongkang Technology has been deeply integrated with the pharmaceutical industry for 18 years, combining advanced AI technology to create significant business value and strategic importance for pharmaceutical companies [1][2] AI Model Capabilities - The "Zhuomuniao Medical Model" has a scale of 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, clinical guidelines, and drug instructions, thus providing precise understanding and key information extraction [2] - The hub offers a comprehensive AI application ecosystem that empowers individuals, facilitates organizational collaboration, and fosters technological innovation [2] Individual Empowerment - The commercial intelligent agent of Tiangong No.1 provides seven professional capabilities, significantly enhancing the efficiency of pharmaceutical professionals, such as reducing the time to generate evidence reports from weeks to minutes, achieving a sevenfold increase in efficiency [2] Organizational Collaboration - The "Enterprise Growth Workbench" addresses the challenges of multi-department collaboration in pharmaceutical companies, featuring over 100 intelligent agents that enhance departmental efficiency across the entire pharmaceutical marketing chain [3] - This model breaks down departmental barriers and fosters competitive growth through a "single-point breakthrough × collaborative evolution" approach [3] Technical Foundation - The intelligent agent center serves as the technical foundation of the hub, driven by both the "Zhuomuniao Medical Model" and the "Tiangong No.1 Decision Model," integrating comprehensive market data and industry experience [3] - The multi-model collaboration capability allows for effective responses to complex medical tasks, ensuring knowledge freshness and decision relevance [3] Industry Impact - The launch of the hub is not just a technological advancement but also a foundational infrastructure for the intelligentization of the health industry, aiming to redefine work methods and decision-making processes [4] - Zhongkang Technology aspires to be a standard setter and connector in the health industry AI application ecosystem, promoting an open, innovative, and win-win environment [4][5]

Core Insights - Zhongkang Technology has launched the "Tiangong No.1 Health Industry AI Application Capability Hub," marking a new phase in the intelligent transformation of the health industry [1][9] - The "Zhuomuniao Medical Model" achieved the top rank in the "Medical Language Understanding" category on the MedBench evaluation platform, highlighting its leading position in the pharmaceutical AI sector [1][2] Group 1: Technological Leadership - The "Zhuomuniao Medical Model" boasts 70 billion parameters, enabling it to deeply analyze vast amounts of medical literature, thus providing precise understanding and extraction of key information [2] - This model addresses the limitations of general AI in the medical field, establishing a solid foundation for deep applications of AI in the health industry [2] Group 2: Industry Value - The "Tiangong No.1 Health Industry AI Application Capability Hub" integrates 18 years of Zhongkang's pharmaceutical industry data and experience, creating a comprehensive AI application ecosystem [3] - The commercial intelligent agent within the hub enhances individual efficiency, allowing medical professionals to generate evidence reports in minutes, increasing productivity by up to 7 times [3] Group 3: Organizational Collaboration - The "Enterprise Growth Workbench" addresses inter-departmental collaboration challenges by providing over 100 intelligent agents that enhance efficiency across the pharmaceutical marketing chain [5][6] - This model breaks down departmental barriers, fostering competitive growth through collaborative evolution [6] Group 4: Strategic Significance - The hub aims to serve as a foundational infrastructure for the intelligent upgrade of the health industry, connecting all segments from research and development to production and distribution [8] - It seeks to redefine operational methods and decision-making processes in the health industry, promoting a new paradigm of human-machine collaboration [8] - Zhongkang Technology is positioned to become a standard setter and connector in the health industry AI application ecosystem, driving innovation and collaboration [8][9]

Core Insights - The pharmaceutical sector is expected to recover from 2025 onwards, following a four-year adjustment period, with a cumulative increase of 4.57% in the pharmaceutical and biological industry as of May 30, 2025 [1][2] - The report suggests focusing on innovative drug companies with solid R&D foundations and competitive products for international markets, as well as traditional pharmaceutical companies with reasonable valuations [1] - AI is anticipated to empower the entire pharmaceutical supply chain, enhancing efficiency in drug development, production, and medical services [2] Group 1: Market Recovery - The pharmaceutical sector has experienced a recovery since 2025, ranking 6th among 31 primary industries in terms of performance, with a cumulative increase of 4.57% [1] - The holding of pharmaceutical stocks has increased but remains at historically low levels [1] - Multiple sub-sectors within the pharmaceutical industry are showing signs of stabilization and upward trends [1] Group 2: Growth Opportunities - Incremental opportunities are expected from innovative drugs and AI, while structural opportunities may arise from the recovery of left-side assets and valuation adjustments [2] - 2025 is projected to be a significant year for domestic innovative drugs entering international markets, with many companies transitioning from generic to innovative drugs since the "4+7" procurement policy in 2018 [2] - Some pioneering innovative drug companies are anticipated to reach breakeven and turn profitable [2] Group 3: Left-Side Assets - Left-side assets are entering a mild recovery phase, with traditional pharmaceutical companies, CXO, and consumer healthcare sectors gradually clearing existing risks [2] - The industry is expected to see a fundamental recovery as the risks associated with previous procurement policies and demand issues diminish [2]

Market Performance - As of May 7, 2025, the Hang Seng Healthcare Index (HSHCI) decreased by 3.02%, with mixed performance among constituent stocks [3] - Leading gainers included Yuan Da Pharmaceutical (00512) up 12.52%, Shanghai Pharmaceuticals (02607) up 2.23%, and China Traditional Chinese Medicine (00570) up 1.96% [3] - Major decliners were Sangfor Technologies (01530) down 8.40%, Ascentage Pharma-B (06855) down 8.13%, and BeiGene (06160) down 7.70% [3] - The Hang Seng Healthcare ETF (513060) fell by 2.65%, closing at 0.48 yuan, with an active trading volume of 1.096 billion yuan [3] Investment Insights - Dongfang Securities noted that the continuous release of diagnostic and treatment demand, along with the commercialization of domestic innovative products, is leading to marginal improvements in certain sectors [3] - The firm believes that the upcoming quarters will see confirmed industry growth due to supply-side innovations driving rapid demand growth, suggesting that now is an excellent time to allocate resources to the healthcare sector [3] Future Investment Trends - Guolian Minsheng Securities anticipates that overseas expansion of innovative drugs, AI integration, and left-side asset valuation recovery will be key investment themes in the pharmaceutical sector for 2025 [4] - Recommendations include traditional pharmaceutical companies with manageable risks and reasonable valuations, as well as innovative drug companies with strong R&D foundations and competitive products for overseas markets [4] ETF Performance Metrics - As of May 6, 2025, the Hang Seng Healthcare ETF has seen a 28.71% increase in net value over the past year [5] - The ETF's highest monthly return since inception was 28.34%, with an average monthly return of 6.79% [5] - The ETF's management fee is 0.50%, and the tracking error is 0.041%, indicating high tracking precision compared to similar funds [5] Top Holdings - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.17% of the index, with major players including BeiGene (06160) and WuXi Biologics (02269) [6][8]